Company profile
Sairopa B.V.
Privately held: no public share price (Clinical-stage immuno-oncology company owned by Van Herk Investments since 2021; not separately listed. Parent: Van Herk Investments (private). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.sairopa.com/cancer-immunotherapy-development-by-sairopa-under-ownership-of-van-herk-investments/]) · Netherlands
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | SIRPα (Signal regulatory protein alpha)Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.